These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35422338)

  • 1. Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
    Barrington DA; Riedinger C; Haight PJ; Tubbs C; Cohn DE
    Gynecol Oncol; 2022 Jun; 165(3):500-505. PubMed ID: 35422338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.
    Lin YT; Wang C; He XY; Yao QM; Chen J
    Front Immunol; 2023; 14():1345942. PubMed ID: 38274823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Shi Y; Chen J; Shi B; Liu A
    Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Barrington DA; Haight PJ; Calhoun C; Tubbs C; Cohn DE; Bixel KL
    Gynecol Oncol; 2021 Sep; 162(3):626-630. PubMed ID: 34148720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China.
    Zheng Z; Song X; Qiu G; Xu S; Cai H
    Curr Med Res Opin; 2023 Mar; 39(3):433-440. PubMed ID: 36757780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
    Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
    Zhan M; Xu T; Zheng H; He Z
    Front Public Health; 2022; 10():790225. PubMed ID: 35309225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.
    Weng X; Luo S; Lin S; Zhong L; Li M; Xin R; Huang P; Xu X
    Oncol Res; 2020 Mar; 28(2):117-125. PubMed ID: 31610828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
    Yang SC; Ou HT; Su WC; Wang SY
    Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.
    Zheng Z; Lin J; Zhu H; Cai H
    Front Public Health; 2022; 10():893387. PubMed ID: 35774581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
    She L; Tian K; Han J; Zuo W; Wang Z; Zhang N
    Oral Oncol; 2022 Jun; 129():105871. PubMed ID: 35483156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Barrington DA; Dilley SE; Smith HJ; Straughn JM
    Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
    Criss SD; Palazzo L; Watson TR; Paquette AM; Sigel K; Wisnivesky J; Kong CY
    PLoS One; 2020; 15(1):e0228288. PubMed ID: 31995619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
    Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T
    J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
    Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
    Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 18. Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
    Nishio S; Yonemori K; Usami T; Minobe S; Yunokawa M; Iwata T; Okamoto A; Aoki Y; Itamochi H; Takekuma M; Harano K; Yamamoto K; Maruko T; Ugai H; Tekin C; Colombo N; Fujiwara K; Hasegawa K; Ushijima K
    Cancer Sci; 2022 Nov; 113(11):3877-3887. PubMed ID: 35792064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
    Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Ejzykowicz F; Burke T
    Curr Med Res Opin; 2019 Jul; 35(7):1241-1256. PubMed ID: 30649973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.